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Miranda Barton
I. CANADIAN PHARMACEUTICAL COMPANY SEEKS
DAMAGES UNDER NAFTJA FROM UNITED STATES
FOR IMPORT RESTRICTIONS ON GENERIC
PRESCRIPTION DRUGS

CANADIAN

pharmaceutical manufacturer Apotex Holdings, the

largest generic drug maker in Canada, requested institution of arbitration proceedings concerning an import alert issued by the
U.S. Food and Drug Administration (FDA) in 2009.1 The pharmaceutical
company was restricted from exporting its generic prescription drugs to
the United States pending an FDA evaluation of the manufacturer's
safety and quality controls. 2 Although the ban was lifted in July 2011,
Apotex has since filed a complaint under NAFTA, claiming that the
United States is liable for $520 million in damages that it suffered in lost
export volume as a result of the import restrictions. 3
A.

THE INITIAL CONCERNs REGARDING APOTEX AND THE FDA
IMPORT RESTRICTIONS

The FDA first issued a warning letter to Apotex in June 2009 and then
issued a second letter in April 2010.4 Observers called the practice of
issuing two letters within one year "unusual." 5 The warning letters cited
problems including "charred particles in a diabetes drug; contamination
of an antihistamine, and drug cross-contamination that resulted from inadequate cleaning of manufacturing equipment," and failure to notify the
FDA about such problems. 6 The first letter, from June 2009, included
1. Dana Flavelle, Apotex Drug Maker Sues U.S. for $520 Million Under NAFTA,
TORoNTo STAR, Mar. 14, 2012, available at http://www.thestar.com/business/article/1146372-apotex-drug-maker-sues-u-s-for-520-million-under-nafta.
2. Letter from Teddi Lopez for Richard L. Freidman, Dir., U.S. Food and Drug Admin., to Jack M. Kay, President and COO, Apotex, Inc. (Mar. 29, 2010), http://
www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm207508.htm.
3. Flavelle, supra note 1.
4. Natasha Singer, F.D.A. Again Warns a Generic Maker About Conditions at Its
Plants, N.Y. TIMES (Apr. 15, 2010), http://www.nytimes.com/2010/04/16/business/
16generic.html.
5. Id.
6. Id.
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what the FDA referred to as "significant violations of the Current Good
Manufacturing Practice (CGMP) regulations for Finished Pharmaceuticals." 7 These violations occurred at the Etobicoke, Ontario manufacturing location and included failure to report the nonconformities with
CGMP regulations as well as the safety and quality control violations
themselves.8
A subsequent inspection of the company's Toronto, Ontario location in
July and August 2009 revealed several violations identical to those cited
at the Etobicoke location; the manufacturer had also failed to report
these violations to the FDA. 9 In light of the repeated violations at the
two plants along with Apotex's failure to report them as required under
FDA regulations, the agency placed both Apotex locations under an import alert as of August 28, 2009.10 The import alert imposed by the FDA
restricted all "finished drug products offered for entry into the United
States" that were manufactured at either the Etobicoke or Toronto
Apotex locations.' Such products were "detained without physical examination" prior to their entry into the United States.12
The specific CGMP violations that the FDA cited in its 2010 letter included failure to have "adequate written procedures for production and
process controls" to ensure that the products "have the identity, strength,
quality, and purity they purport or are represented to possess."' 3 The
FDA also cited the company's failure to "thoroughly investigate unexplained discrepancies or the failure of a batch or any of its components to
meet any of its specifications," such as the discovery of contaminants in
batches of finished pharmaceuticals without a subsequent follow-up investigation to determine the source of the contaminants. 14 The FDA's
third violation cited Apotex's failure to have "adequate equipment cleaning and maintenance procedure[s]."1 5 The agency referenced instances of
finding "foreign materials," "charred material," and "powder residues" in
the finished pharmaceutical products, and also of defective finished products or materials being returned back into inventory upon discovery of
16
contaminants or foreign material.
B.

APOTEX'S CORRECTIVE AcTIONs

After issuance of the FDA warning letter, Apotex acknowledged "certain shortcomings in its operations" and voluntarily recalled certain prod7. Letter from Teddi Lopez to Jack M. Kay, supra note 2.
8. Id.
9. Id. Such reports (NDA Field Alert Reports) are required by 21 CFR
§ 314.81(b)(1) and § 505(k) of the Federal Food, Drug, and Cosmetic Act (21
U.S.C. § 355(k)).
10. Id.
11. Id.
12. Id.
13. Id.
14. Id.
15. Id.
16. Id.
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ucts.' 7 This included about 659 batches of prescription generics recalled
from July 2007 until August 2009.18 Apotex says that it corrected the
issues cited by the FDA in its warning letters and noted that other countries did not ban its products from import.' 9 It also points out that Health
Canada gave the two plants, cited by the FDA, "a passing grade" in 2009,
after the alleged violations had been remedied. 20 The FDA asserted that
at the time of the warning letter, the company had "serious and repeat
violations from the 2008 and 2009 inspections" and had demonstrated an
"inadequate" response to prior warnings. 2 1
As a result of the corrective actions taken by the company in July 2011,
the FDA issued a close-out letter regarding the violations. 22 Although an
FDA close-out letter is not a protection from future regulatory action
regarding violations, the letter did acknowledge that the company had
"addressed the violations" from the March 29, 2010 warning letter.23
Apotex complains that the letter was unnecessarily delayed by various
FDA actions including subsequent inspections, administrative delays, and
repeated inspections during the import alert period despite Apotex having corrected the issues cited by the FDA.2 4
C.

APOTEx's LEGAL REsPONSE

Apotex claims that the import restrictions did irreparable damage to its
distribution business in the United States, causing it to fall from the sixth
largest exporter of generic pharmaceuticals at the time the restrictions
were issued, to the twenty-fifth largest exporter by the time they were
lifted. 2 5 Apotex's Request for Arbitration characterizes the import alert
as something that, in practice, "is not detention of any product or sample
but a refusal of admission of all products meeting the stated category,
without examination .. "26 The company claims that the FDA's import
alert "decimated" its U.S. export business. 27 It has filed a suit in the
World Bank Group's International Centre for Settlement of Investment
Disputes seeking $520 million in damages under NAFTA. 28
17.
18.
19.
20.
21.
22.
23.
24.

25.
26.
27.
28.

Flavelle, supra note 1.
Singer, supra note 4.
Flavelle, supra note 1.
Id.
Singer, supra note 4.
Letter from Maan Abduldayem, Compliance Officer, U.S. Food and Drug Admin.,
to Jeremy B. Desai, Chief Operating Officer, Apotex. Inc. (July 1, 2011),
www.fda.gov/ICECI/EnforcementActions/WarningLetters/2010/ucm267086.htm.
Id.
See Apotex Holdings Inc. and Apotex Inc. v. United States, ICSID Case No.
ARB(AF)/12/1, Request for Arbitration, 1 54-56 (Feb. 29, 2012), available at
http://www.state.gov/documents/organization/185626.pdf [hereinafter Apotex Request for Arbitration].
Flavelle, supra note 1.
Apotex Request for Arbitration, supra note 24, 1 25.
Apotex Sues Government, Says 2009 Import Ban 'Decimated' Its U.S. Business,
FDANEWS (Mar. 19, 2012), http://www.fdanews.com/newsletter/article?issueld=
15605&articleld=144887.
Id.
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In the suit, Apotex claims that it quickly recalled the affected drugs,
but despite its prompt attention, the United States failed to withdraw the
import alert until nearly two years later.29 The company says that the ban
was not only "devastating" to the company's distribution, but also that it
was discriminatory because other pharmaceutical companies with similar
violations were not punished as strictly.30 In response to the alleged unfair treatment, the company filed a challenge against the United States
under Chapter 11 of NAFTA. 31
Specifically, Apotex alleges that by enforcing the import alert against
the Etobicoke and Toronto manufacturing plants, "the United States accorded [Apotex] treatment less favorable than that afforded to U.S. investors in like circumstances regarding the establishment, acquisition,
expansion, management, conduct, operation and sale of investments in
the form of authorizations to sell pharmaceutical products and other investments in the U.S."3 2 Apotex claims that U.S.-owned rivals were afforded more favorable treatment by the FDA, citing a U.S.-owned
pharmaceutical plant in Israel as an example.3 3 Apotex alleges that such
favorable treatment violates NAFTA Article 1102, which states in part
that "each Party shall accord to investors of another Party treatment no
less favorable than that it accords, in like circumstances, to its own investors with respect to the establishment, acquisition, expansion, management, conduct, operation, and sale or other disposition of investments." 3 4
II.

UNITED STATES INSTITUTES CAFTA-DR ACTION
AGAINST GUATEMALA FOR ALLEGED LABOR
LAW VIOLATIONS

In August 2011, the Office of the United States Trade Representative
announced that the United States would request an arbitral panel under
the CAFTA-DR to evaluate claims that Guatemala was failing to enforce
its own labor rights laws (as required by the free trade agreement) and
Guatemala's lack of a satisfactory response to the allegations.3 5 Since
then, the two CAFTA-DR signatory countries have been engaged in informal negotiations but have failed to resolve the dispute.36 The formal
request for a decision from the CAFTA-DR Free Trade Commission is
29. Jeff Gray, Apotex Challenges U.S. Import Ban under NAFTA, GLOBE AND MAIL,

Mar. 15, 2012, at B3.
Id.
Id.
Apotex Request for Arbitration, supra note 24, T 69 (citing NAFTA Article 1102).
Flavelle, supra note 1; see also Apotex Request for Arbitration, supra note 24, 1
69.
34. Apotex Request for Arbitration, supra note 24, 1 25.
35. Press Release, U.S. Trade Representative Ron Kirk Announces Next Step in Labor Rights Enforcement Case against Guatemala (Aug. 9, 2011), availableat http://
www.ustr.gov/about-us/press-office/press-releases/2011/august/us-trade-representative-ron-kirk-announces-next-ste.
36. See U.S., Guatemala Take Another Stab at Resolving CAFTA Labor Fight, 29 INSIDE U.S. TRADE 50 (2011).
30.
31.
32.
33.
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the first labor case brought by the United States against another party to
one of its free trade agreements. 37
A.

HISTORY OF THE DISPUTE

In July 2010, the United States formally requested that Guatemala respond to allegations that it was violating its own labor rights laws. 3 8
CAF[A-DR, which governs free trade between the United States and the
Central American nations, along with the Dominican Republic, requires
that each nation enforce its own labor laws adequately.3 9 The request
referred back to an April 2008 filing by the United States' American Federation Labor-Congress of Industrial Organizations and six Guatemalan
labor rights organizations. 40 That filing claimed that Guatemala was failing to enforce its own laws regarding "the right of association, the right of
workers to organize and bargain collectively, and acceptable conditions
of work." 41 Further, labor rights leaders in Guatemala claimed that they
were systematically excluded from discussions regarding labor rights between the Guatemalan government and the United States. 4 2
Since the submission and subsequent investigation by the United
States, the U.S. Trade Representative and the U.S. Departments of Labor
and State examined Guatemalan compliance with the requisite that it enforces those laws relating to labor rights. Consultations between the
agencies and the Guatemalan government took place in 2010, and the
United States requested a meeting of the Free Trade Commission in
2011.43 Although negotiations have continued, the governments of the
United States and Guatemala have been unable to reach agreement regarding "an adequate enforcement plan" for the labor rights guaranteed
by Guatemala's labor laws. 4 4 In light of this failure, the United States has
moved on to requesting an arbitral panel to evaluate the violations.
According to an AFL-CIO official, if the complaint were fully adjudicated and Guatemala were found to have violated its own labor laws, the
nation "could be assessed a maximum fine of $15 million, which it would
pay to itself to address the underlying problems." 45 Failure to pay the
37. Amy Tsui, USTR Takes Next Step Against Guatemala in CAFTA-DR Labor Law
Enforcement Case, 28 INr'L TRADE REP. 824 (2011).

38. Rossella Brevetti, U.S. Seeks Arbitration Panel in Labor Case Against Guatemala
Brought Under CAFTA-DR, 28 INT'L TRADE REP. 1322 (2011).
39. Id.
40. See John Crook, Contemporary Practice of the United States Relating to International Law: Settlement of Disputes: United States Initiates CAFTA-DR Labor Law
Arbitration Against Guatemala, 105 AM. J. or INT'L LAw 812 (2011).
41. See id. at 813.
42. Matthew Walter, U.S. Leans on Guatemala to Enforce Trade Pact, CHRISTIAN SCI.

MONITOR (July 13, 2011), http://www.csmonitor.com/World/Americas/2011/0713/
US-leans-on-Guatemala-to-enforce-trade-pact.
43. See Crook, supra note 40, at 813 (noting that the Commission met on June 7, 2011
and stating that the Commission is composed of members from each of the member countries).
44. Id.

45. Tsui, supra note 37.
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fine and address the violations, if the tribunal found Guatemala to be in
violation, could result in trade sanctions by the United States. 46
B.

GUATEMALA'S RESPONSE

In December 2011, Guatemalan Economic Minister Luis Velasquez announced that the two countries were informally negotiating to "find an
alternative route to resolv[e] the labor dispute without resorting to a
panel." 47 Guatemala had previously agreed to fourteen of the seventeen
points raised by the United States to resolve the dispute and bring Guatemala into compliance with its own labor regulations. 4 8
One of the three remaining disputes was for Guatemala to "hire and
train 100 additional labor inspectors," which Velasquez indicated that the
country was now ready to do. 4 9 The two remaining issues "involve returning to the labor ministry the power to sanction employers for noncompliance with labor laws and requiring businesses operating under a
special law promoting the growth of 'maquilas' to post a bond that would
compensate workers in the event the business closes." 50
Guatemala claims that returning the power to sanction employers to
the labor ministry would violate the country's constitution because the
power is vested in the country's labor courts. 5 ' Velasquez said that it
would continue to negotiate to resolve the two remaining issues, but
noted that the country would not "propose improvements or changes to
the constitution." 52 The nation also claims that it would be unfair to require the bonding for certain maquilas retroactively, and has not proposed an alternative arrangement for either of these two disputed
issues. 53 A U.S. Trade Representative spokeswoman said that the United
States believed that the steps it is requesting of Guatemala "could be
taken in a manner consistent with Guatemala's constitution and its laws,
and, were Guatemala to take such steps, we believe they could lead to
resolution of this matter." 54
Guatemala also alleges that the United States did not have grounds
under CAFTA 16.2 to bring the action because it did not show that the
outstanding issues alleged by the United States actually affected trade
between the countries.5 5 Article 16.2 of the CAFTA-DR agreement
states that a party "shall not fail to effectively enforce its labor laws,
through a sustained or recurring course of action or inaction, in a manner
46. Id.
47. See U.S., Guatemala Take Another Stab at Resolving CAFTA Labor Fight, supra
note 36.
48. Id.
49. Id.
50. Id.
51. Id.
52. Id.
53. Id.

54. Id.
55. Id.
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affecting trade between the parties." 56 Guatemala claims that even if the
issues alleged by the United States are true, they have not affected trade
between the two countries.5 7

56. Dominican Republic-Central America-United States Free Trade Agreement art.
16.2, Aug. 23, 2010, 75 FR 51869, USTR-2010-0023.
57. See U.S., Guatemala Take Another Stab at Resolving CAFTA Labor Fight, supra
note 36.
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